VAL Valirx Plc

TIDMVAL

RNS Number : 3581A

ValiRx PLC

29 September 2020

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Exercise of Warrant

London, UK 29 September 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces it has received notification for the exercise of warrants over 60,000 ordinary shares in the Company at an exercise price of 25 pence per share providing the Company with proceeds of GBP15,000 ("Warrant Exercise").

Application will be made to the London Stock Exchange to admit the 60,000 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 2 October 2020. The new ordinary shares will rank pari passu with the existing ordinary shares.

For the purposes of the Disclosure and Transparency Rules, following the issue of shares detailed above as a result of the Warrant Exercise, the enlarged issued share capital of the Company will comprise 58,849,423 ordinary shares of 0.1 pence each. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information please contact:

 
 ValiRx plc                                       Tel: +44 (0) 20 7073 
                                                    2628 
                                                    www.valirx.com 
  Suzanne Dilly                                    Suzanne.Dilly@valirx.com 
 
   Cairn Financial Advisers LLP (Nominated          Tel: +44 (0) 20 7213 
   Adviser)                                         0880 
   Liam Murray / Jo Turner / Ludovico Lazzaretti 
 
   Peterhouse Capital Limited (Sole Broker)         Tel: +44 (0) 20 7469 
   Duncan Vasey / Lucy Williams / Eran Zucker       0930 
 
   Optimum Strategic Communications                 Tel: +44 (0) 20 8148 
   Supriya Mathur/ Shabnam Bashir                   3040 
                                                    valirx@optimumcomms.com 
 
 
 About ValiRx 
 ValiRx accelerates the development 
 of treatments in oncology and 
 women's health to improve patient 
 lives. We provide the scientific, 
 financial and commercial framework 
 to enable rapid translation 
 of innovative science into 
 clinical development. 
 
 With our extensive and proven 
 experience in research and 
 drug development, we select 
 and incubate promising novel 
 drug candidates and guide them 
 through an optimised process 
 of development, from pre-clinical 
 studies to clinic and investor-ready 
 assets. 
 
 Integrating science and business 
 We connect diverse disciplines 
 across scientific, technical 
 and commercial domains, with 
 the promise of achieving a 
 more streamlined, less costly, 
 drug development process. We 
 work closely with our selected 
 collaborators and leverage 
 the combined expertise required 
 for science to advance. 
 
 Lead candidates from our portfolio 
 are out-licenced or partnered 
 with investors through ValiRx 
 subsidiary companies for further 
 clinical development and commercialisation. 
 https://www.valirx.com/ 
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ALSEAKNPASXEEFA

(END) Dow Jones Newswires

September 29, 2020 02:00 ET (06:00 GMT)

Valirx (LSE:VAL)
Historical Stock Chart
From Mar 2024 to Apr 2024

Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2023 to Apr 2024